Filing Flows › Companies › X4 Pharmaceuticals › Timeline
X4 Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−9.2% to $3.18
X4 Pharmaceuticals (XFOR) stock fell 9% over the last 252 sessions, to $3.18. On the way it reported 4 quarters, its insiders filed 4 open-market trades and 3 Form 144 notices of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026 | Earnings | Earnings: beat the EPS estimate by 14.0% | +2.2% (+0.5% vs SPY) | — | — |
| Oct 8, 2026 | 8-K | Material definitive agreement | +4.2% (+3.6% vs SPY) | −5.5% (−5.2% vs SPY) | +13.1% (+18.2% vs SPY) |
| Oct 1, 2026 | Form 144 | Form 144: David Kirske plans to sell $34K | −2.4% (−2.6% vs SPY) | −3.2% (−5.1% vs SPY) | +14.7% (+13.9% vs SPY) |
| Aug 12, 2026 | Form 144 | Form 144: Adam Craig plans to sell $216K | +0.2% (0.0% vs SPY) | −1.7% (−1.3% vs SPY) | −23.0% (−21.4% vs SPY) |
| Aug 12, 2026 | Form 144 | Form 144: John Volpone plans to sell $112K | +0.2% (0.0% vs SPY) | −1.7% (−1.3% vs SPY) | −23.0% (−21.4% vs SPY) |
| Aug 12, 2026 | Insider sale | Volpone John sold $109K | +0.2% (0.0% vs SPY) | −1.7% (−1.3% vs SPY) | −23.0% (−21.4% vs SPY) |
| Aug 12, 2026 | Insider sale | Craig Adam R sold $211K | +0.2% (0.0% vs SPY) | −1.7% (−1.3% vs SPY) | −23.0% (−21.4% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 27.8% | +0.5% (+0.6% vs SPY) | +3.3% (+3.0% vs SPY) | −2.7% (−3.1% vs SPY) |
| Jul 1, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.1% (+1.2% vs SPY) | −3.1% (−3.9% vs SPY) | −2.6% (−2.8% vs SPY) |
| Jun 30, 2026 | Insider sale | Kirske David sold $36K | +9.9% (+9.1% vs SPY) | −7.1% (−8.0% vs SPY) | −5.6% (−4.0% vs SPY) |
| May 13, 2026 | 8-K | Directors and officers: departures, appointments, pay | −5.6% (−6.4% vs SPY) | −11.5% (−11.4% vs SPY) | −5.6% (−5.5% vs SPY) |
| May 12, 2026 | 8-K | Directors and officers: departures, appointments, pay | −2.6% (−3.1% vs SPY) | −17.6% (−17.0% vs SPY) | −11.2% (−11.2% vs SPY) |
| May 12, 2026 | Insider sale | Kirske David sold $73K | −3.6% (−3.5% vs SPY) | −20.1% (−20.0% vs SPY) | −18.8% (−16.9% vs SPY) |
| May 6, 2026 | Earnings | Earnings: beat the EPS estimate by 20.0% | +4.2% (+2.8% vs SPY) | +3.3% (+1.3% vs SPY) | −4.6% (−9.1% vs SPY) |
| Mar 17, 2026 | Earnings | Earnings: beat the EPS estimate by 36.7% | +17.2% (+17.0% vs SPY) | +13.4% (+15.2% vs SPY) | +19.6% (+14.8% vs SPY) |
Insiders’ record here
In the year on the chart, X4 Pharmaceuticals' insiders reported 0 open-market buys ($0) and 4 sales ($429K). Of the 2 old enough to score, 2 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −5.8%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 1.02 Termination of a material agreement | 2,368 | 0.0% | 51% | +1.1% | ±1.5% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → X4 Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.